DeepMed Research

UNIVERSITY COLLEGE LONDON

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Private

Established: 1826-02-11

Employees: 10K

Market Cap: -

Website: http://www.ucl.ac.uk

Clinical Trials

Prognostic Models for People With Stable Coronary Artery Disease

Conditions: Stable Coronary Artery Disease

First Posted Date: 2012-06-01

Last Posted Date: 2012-06-01

Lead Sponsor: University College, London

Target Recruit Count: 300000

Registration Number: NCT01609465

Locations: 🇬🇧
Clinical Epidemiology Group, UCL, London, United Kingdom

A Randomised Trial Investigating the Additional Benefit of Hydroxychloroquine(HCQ)to Short Course Radiotherapy (SCRT) in Patients Aged 70 Years and Older With High Grade Gliomas (HGG)

Phase 2

Completed

Conditions: Glioblastoma

Interventions: Radiation: Radiotherapy
Drug: Hydroxychloroquine

First Posted Date: 2012-05-21

Last Posted Date: 2018-05-03

Lead Sponsor: University College, London

Target Recruit Count: 54

Registration Number: NCT01602588

Locations: 🇬🇧
Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
🇬🇧
St James's University Hospital, Leeds, West Yorkshire, United Kingdom
🇬🇧
Ninewells Hospital, Dundee, United Kingdom

and more 12 locations

Trial of Haploidentical Stem Cell Transplantation for Haematological Cancers

Phase 2

Completed

Conditions: Hodgkin's Lymphoma
Chronic Myeloid Leukaemia
Non-Hodgkin's Lymphoma
Acute Lymphoblastic Leukaemia
Acute Myeloid Leukaemia
Myelodysplastic Syndrome
Acquired Bone Marrow Failure Syndromes
Other Haematological Malignancies; Unrelated HSCT Indicated
Chronic Lymphocytic Leukaemia

Interventions: Procedure: Reduced intensity haplodentical stem cell transplant
Procedure: Myeloablative haploidentical stem cell transplant

First Posted Date: 2012-05-11

Last Posted Date: 2024-05-03

Lead Sponsor: University College, London

Target Recruit Count: 77

Registration Number: NCT01597219

Locations: 🇬🇧
Bristol Royal Infirmary, Bristol, United Kingdom
🇬🇧
Birmingham Heartlands, Birmingham, United Kingdom
🇬🇧
Addenbrooke's Hospital, Cambridge, United Kingdom

and more 9 locations

Randomised Trial in Waldenstrom's Macroglobulinaemia

Phase 2

Completed

Conditions: Waldenstrom's Macroglobulinaemia

Interventions: Drug: Bortezomib
Drug: Cyclophosphamide
Biological: Rituximab
Drug: Fludarabine

First Posted Date: 2012-05-07

Last Posted Date: 2021-06-18

Lead Sponsor: University College, London

Target Recruit Count: 60

Registration Number: NCT01592981

Locations: 🇬🇧
University College Hospital, London, United Kingdom
🇬🇧
King's College Hospital, London, United Kingdom
🇬🇧
Maidstone Hospital, Maidstone, United Kingdom

and more 27 locations

Ganetespib With Platinum, in Patients With Malignant Pleural Mesothelioma

Phase 1

Completed

Conditions: Lung Cancer - Malignant Pleural Mesothelioma

Interventions: Drug: Ganetespib

First Posted Date: 2012-05-02

Last Posted Date: 2019-11-13

Lead Sponsor: University College, London

Target Recruit Count: 27

Registration Number: NCT01590160

Locations: 🇬🇧
UCL Cancer Trials Centre, London, United Kingdom

Induction Chemotherapy Plus Chemoradiation as First Line Treatment for Locally Advanced Cervical Cancer

Phase 3

Active, not recruiting

Conditions: Cervical Cancer

Interventions: Drug: Paclitaxel
Drug: Cisplatin
Drug: Carboplatin
Radiation: Radiotherapy

First Posted Date: 2012-03-29

Last Posted Date: 2024-12-05

Lead Sponsor: University College, London

Target Recruit Count: 500

Registration Number: NCT01566240

Locations: 🇬🇧
Royal Derby Hospital, Derby, United Kingdom
🇬🇧
Pilgrim Hospital, Boston, United Kingdom
🇬🇧
The Clatterbridge Cancer Centre, Wirral, United Kingdom

and more 32 locations

The Activity of TroVax® Versus Placebo in Relapsed Asymptomatic Ovarian Cancer

Phase 2

Completed

Conditions: Peritoneal Cancer
Fallopian Tube Cancer
Ovarian Cancer

Interventions: Biological: TroVax®
Biological: Placebo

First Posted Date: 2012-03-16

Last Posted Date: 2019-05-09

Lead Sponsor: University College, London

Target Recruit Count: 94

Registration Number: NCT01556841

Locations: 🇬🇧
The Clatterbridge Cancer Centre NHS Foundation Trust, Bebington, Wirral, United Kingdom
🇬🇧
Leeds Teaching Hospitals NHS Trust, Leeds, West Yorkshire, United Kingdom
🇬🇧
University Hospitals of Bristol NHS Foundation Trust, Bristol, United Kingdom

and more 9 locations

Bortezomib Consolidation Trial

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Bortezomib

First Posted Date: 2012-01-25

Last Posted Date: 2019-04-17

Lead Sponsor: University College, London

Target Recruit Count: 40

Registration Number: NCT01517724

Locations: 🇬🇧
University College London, London, United Kingdom

Physiological Response to Heliox21 and Air O2

Phase 4

Conditions: Respiratory Insufficiency

Interventions: Drug: Heliox21
Drug: Air O2

First Posted Date: 2011-12-23

Last Posted Date: 2011-12-23

Lead Sponsor: University College, London

Target Recruit Count: 38

Registration Number: NCT01498432

Locations: 🇬🇧
Whittington Hospital NHS Trust, London, United Kingdom

Phase I Study of Olaparib With Cisplatin Based Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck

Phase 1

Withdrawn

Conditions: Carcinoma, Squamous Cell

Interventions: Drug: olaparib
Drug: cisplatin
Radiation: Intensity Modulated Radiotherapy

First Posted Date: 2011-12-13

Last Posted Date: 2012-05-30

Lead Sponsor: University College, London

Registration Number: NCT01491139

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy